insights_auto
Why is KYNB up 2.85%?
Dive Deeperchevron_right
KYNB:NASDAQ
Kyntra Bio Inc
$6.13
arrow_upward
+2.85%(+0.17) 1D
Oct 7, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KYNB...
Open
$5.85
High
$6.35
Low
$5.85
Mkt. cap
24.82M
Avg. vol.
26.52K
Volume
16.83K
P/E ratio
0.14
52-wk high
$9.70
52-wk low
$5.62
EPS
$45.30
Beta
1.05
Shares outstanding
4.05M
No. of employees
34
Open
$5.85
High
$6.35
Low
$5.85
Mkt. cap
24.82M
Avg. vol.
26.52K
Volume
16.83K
P/E ratio
0.14
52-wk high
$9.70
52-wk low
$5.62
EPS
$45.30
Beta
1.05
Shares outstanding
4.05M
No. of employees
34
News stories
From web sources and news partners
Investing.com Canada
·
1 day ago
Form 4 Kyntra Bio Inc For: 6 October By Investing.com
Stock Titan
·
1 day ago
A director receives 14,000 Kyntra Bio (KYNB) stock options with a $6.50 exercise price.
TipRanks
·
1 day ago
Kyntra Bio Faces Nasdaq Delisting, Appeals Listing Decision
AD HOC NEWS
·
2 days ago
Kyntra Bio stock falls 3.02 percent as board changes
Profile
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
About Kyntra Bio Inc
CEO-
Employees34
FoundedJan 1, 1993
HeadquartersSan Francisco, California, United States
SectorBiotechnology
Websitekyntrabio.com